Print

New FDA approval of PARP inhibitor for maintenance therapy in ovarian cancer

https://www.facingourrisk.org/XRAY/fda-approval-niraparib-maintenance
Full article: https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-niraparib-first-line-maintenance-advanced-ovarian-cancer

The FDA has approved the use of niraparib (Zejula) as a maintenance therapy for women with advanced ovarian cancer who have had a complete or partial response to chemotherapy. (5/7/20)

Expert Guidelines

The National Comprehensive Cancer Network (NCCN) is a national panel of experts that creates guidelines for cancer treatment. For women who have had a complete or partial response to fist-line therapy, the NCCN recommends the following:

Questions To Ask Your Health Care Provider

Open Clinical Trials

 

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.